Getting rejected by the FDA is never fun, but sometimes a "no" comes with enough hints about how to get to "yes" that investors actually celebrate. That's essentially what happened Monday when Aquestive Therapeutics (AQST) received a Complete Response Letter from the FDA for Anaphylm, its sublingual film designed to treat severe Type I allergic reactions including anaphylaxis in patients weighing 30kg or more (roughly 66 pounds).

The FDA had already flagged problems back in January, identifying deficiencies in Anaphylm's New Drug Application that prevented the agency from even discussing labeling and post-marketing commitments. Now the complete picture is clearer, and it centers on what the industry calls "human factors" – basically, can people actually use this thing correctly when they desperately need it?

The Packaging Problem

The FDA's concerns focused on the human factors validation study, which tests whether real people can open, handle, and use a medical product properly. In Anaphylm's case, the agency spotted two red flags: some users had difficulty opening the pouch, and others placed the film incorrectly. When you're dealing with anaphylaxis – a potentially life-threatening allergic reaction where seconds matter – these aren't minor quibbles. They're legitimate safety concerns.

Daniel Barber, Aquestive's President and CEO, tried to emphasize the glass-half-full perspective: "While it is unfortunate to have received a CRL... We are encouraged that the issues in the letter are limited to human factors and a supportive PK study, once human factors are addressed, and we noted several labeling comments that will inform the final label for Anaphylm, if approved by the FDA."

The Fix

Aquestive isn't starting from scratch. The company has already modified the pouch opening mechanism, updated the instructions for use, and revised both pouch and carton labeling. The plan now is to quickly conduct a new human factors validation study incorporating these changes. They'll also address potential tolerability issues in the resubmission.

Here's what didn't get questioned: the comparability data Aquestive submitted, including bracketing, repeat dose, and sustainability studies. No chemistry, manufacturing, and controls (CMC) issues were flagged either. That's significant because it means the drug itself isn't the problem – just the delivery mechanism.

The FDA did request one additional pharmacokinetics study to understand how any packaging and labeling modifications might affect drug absorption. The good news? The agency said the human factors study and PK study can run simultaneously, which saves time. No other studies were requested.

Timeline and Global Plans

Aquestive is targeting resubmission in early Q3 2026, assuming the human factors and PK studies wrap up on schedule and the FDA responds at its typical pace. The company plans to request expedited review from the agency.

Beyond the U.S., Aquestive expects to submit its marketing authorization application in Europe and its New Drug Submission in Canada during the second half of 2026. Feedback from the U.K.'s Medicines and Healthcare Products Regulatory Agency is expected in Q1 2026.

Market Impact

William Blair analyst Lachlan Hanbury-Brown noted that the Anaphylm delay gives ARS Pharmaceuticals (SPRY) an extended head start in this market. The analyst expects Anaphylm's approval decision won't come until the first half of 2027, pushing potential competition back by a year or more.

Yet Aquestive shares jumped 45.25% to $4.28 on Monday following the announcement. Apparently, having a clearly defined path forward – even if it's longer than hoped – beats uncertainty about whether your drug will ever get approved at all.